Key result
Type 1 diabetes with microvascular complications is linked to ~33% higher overall hemostatic potential versus controls.
Why the study?
The influence of thrombin activatable fibrinolysis inhibitor (TAFI) on fibrinolysis and hemostatic changes in type I diabetes mellitus patients with and without microvascular complications was unclear.
Are there differences in TAFI levels and hemostatic potential between type I diabetes patients with or without microvascular complications and healthy controls?
Observational (n=58)
Are there differences in TAFI levels and hemostatic potential between type I diabetes patients with or without microvascular complications and healthy controls?
Patients with type I diabetes and microvascular complications exhibit an increased overall hemostatic potential indicating a prothrombotic state, which does not appear to be driven by TAFI.
Answers are grounded in this paper and cite their sources.
Supports prothrombotic state in complicated type 1 diabetes independent of TAFI; hypothesis-generating and requires prospective confirmation before clinical consideration.
We investigated thrombin activatable fibrinolysis inhibitor (TAFI) and its influence on fibrinolysis by measuring pro-TAFI activity and total TAFI antigen in 38 patients with type I diabetes mellitus (18 with and 20 without microvascular complications), as well as in 20 healthy controls. The pro-TAFI levels in the two groups of patients did not differ from those in the control group. Total TAFI antigen [i.e. pro-TAFI, TAFI and inactive carboxypeptidase U (TAFIi)] tended to decrease in both the patient groups (59.7 +/- 7.2 and 73.4 +/- 8.9% with and without microvascular complications, respectively) compared with controls (91.9 +/- 12.2%) (P = 0.12). We also assessed the overall hemostatic potential (OHP) in plasma, the clot lysis time and the overall fibrinolytic potential. The OHP was significantly higher in patients with complications compared with controls (8.9 +/- 0.9 versus 6.7 +/- 0.4; P < 0.05) and also higher in the diabetics without complications (7.8 +/- 0.6), although the latter difference did not reach statistical significance. Levels of clot lysis time and overall fibrinolytic potential were similar in the two groups of patients and the controls. The increased OHP in plasma from diabetic patients with microvascular complications indicates an imbalance of the hemostatic system towards a prothrombotic state. No signs of impaired fibrinolysis were observed in patients with diabetes. Using the OHP method for estimation of overall hemostasis, it seems that TAFI does not influence either fibrinolysis or the increased thrombotic potential observed in patients with type I diabetes mellitus.
No takes yet. Share an insight, caveat, or question.
Antović et al. (2003) conducted an observational in Type I diabetes mellitus (n=58). Type I diabetes mellitus with microvascular complications vs. Healthy controls was evaluated on Overall hemostatic potential (OHP) in plasma (p=<0.05). Overall hemostatic potential was higher in type I diabetes patients with microvascular complications compared with healthy controls, indicating a prothrombotic state.
Synapse has enriched 10 related papers. Consider them for comparative context: